Novo Nordisk A/S (NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) adopted a positive opinion, recommending a label update of its blockbuster weekly injection for chronic weight management, Wegovy (semaglutide 2.4 mg).The CHMP has recommended a label update for Wegovy that reflects reduced heart failure symptoms, improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF), ...